Daunorubicin / Daunomycin

Indications & Dose:

Acute lymphocytic and acute granulocytic leukaemias. Acute myeloblastic leukaemia. Rhabdomyosarcoma and disseminated neuroblastoma. l

• BY INJECTION

Adult 0.8 mg/kg i/v and continue with a maintenance dose of 0.8 -1mg /kg Max. 25 mg/kg.

Children Initial dose of 1mg/kg of daunorubicin by i/v daily for 4-5 days, max. 25 mg/kg. 

Contraindications:

Hypersensitivity to Daunorubicin or any component, CHF or arrhythmias, pre-existing bone marrow suppression. Previous full cumulative doses of doxorubin and/or daunorubicin

Side Effects:

Nausea, vomiting, bone marrow depression, stomatitis, alopecia, rash, hyperpigmentation, cardiotoxicity, CHF, fever and chills. Diarrhoea, severe local tissue damage and necrosis on extravasation. Anaphylactoid reaction, red urine (not haematuria)

Cautions:

Precautions:

Cardiac, haematological monitoring. Hepatic, renal impairment, children, extravasation.
Pregnancy & breast-feeding: Use with caution.
Old age: Use with caution. 

Interaction:

Drugs
Immunisation with live vaccines not recommended as daunorubicin is immunosuppressant. Radiation: Enhanced radiation induced toxicity of myocardium, mucosa, skin and liver. Heparin in solution, aluminium and dexamethasone: Incompatible with these drugs.

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: